menu
    • menu

    Company profile for Synendos Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain. Our mission is to advance the preclinical and clinical development of a new class of small molecules that act as selective endocannabin...
    Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain. Our mission is to advance the preclinical and clinical development of a new class of small molecules that act as selective endocannabinoid reuptake inhibitors (SERIs).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Synendos TherapeuticsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Gewerbestrasse, 24 CH-4123 Allschwil
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.synendos.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/in/andreachicca/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/synendos

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Synendos Therapeutics Unveils Encouraging Phase 1 Results
    Synendos Therapeutics Unveils Encouraging Phase 1 Results

    24 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/24/3155178/0/en/Synendos-Therapeutics-Reports-Positive-and-Highly-Promising-Topline-Results-from-Phase-1-Trials-Paving-the-Way-for-Phase-2-in-Mental-Health.html

    GLOBENEWSWIRE
    24 Sep 2025
    Share Share
    Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for SYT-510
    Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for SYT-510

    18 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synendos-therapeutics-ag-granted-ema-clinical-trial-authorisation-for-first-in-class-endocannabinoid-system-modulator-syt-510-302037349.html

    PR NEWSWIRE
    18 Jan 2024
    Share Share
    Professor Jürg Gertsch, Presents New Findings on an Endocannabinoid Transporter
    Professor Jürg Gertsch, Presents New Findings on an Endocannabinoid Transporter

    18 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synendos-therapeutics-ag-co-founder-and-sab-member-professor-jurg-gertsch-presents-groundbreaking-new-findings-on-an-endocannabinoid-transporter-at-cannabinoid-research-conference-301878746.html

    PR NEWSWIRE
    18 Jul 2023
    Share Share
    Synendos Therapeutics Expands Series A to CHF 24 million with new investment
    Synendos Therapeutics Expands Series A to CHF 24 million with new investment

    20 Apr 2021

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/synendos-therapeutics-expands-series-a-to-chf-24-million-with-new-investment-1622119841.pdf

    PRESS RELEASE
    20 Apr 2021
    Share Share
    Synendos Therapeutics Expands Series A to CHF 24 million with new investment
    Synendos Therapeutics Expands Series A to CHF 24 million with new investment

    19 Apr 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/synendos-therapeutics-expands-series-a-to-chf-24-million-with-new-investment-301271711.html

    PRNEWSWIRE
    19 Apr 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search